Navigation Links
Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
Date:12/8/2011

SUNNYVALE, Calif., Dec. 8, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), announced today that it has entered into a worldwide collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ), to develop and commercialize PCI-32765, a novel, oral, first-in-class Bruton's tyrosine kinase (Btk) inhibitor  being developed for the treatment of Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma, all of which are considered hematological malignancies.  PCI-32765 was developed by Pharmacyclics and is currently in Phase II clinical trials.  

Under the terms of the agreement, Pharmacyclics will receive an upfront payment of $150 million.   In addition, Pharmacyclics will receive up to an additional $825 million in development and regulatory milestone payments, based upon continued development, regulatory progress and approval of the product, for total potential upfront and milestone payments of $975 million. 

Pharmacyclics and Janssen will collaborate on the development of PCI-32765 for oncology and other indications, excluding inflammation and immune mediated conditions.  Each company will lead development for specific indications as stipulated in a global development plan, with development costs shared on a 40/60 basis (Pharmacyclics 40% and Janssen 60%).  The agreement includes plans to launch multiple Phase III trials of PCI-32765 over the next several years.

Following regulatory approval, both Pharmacyclics and Janssen will book revenue and co-commercialize PCI-32765.   In the US, Pharmacyclics will book sales and take a lead role in US commercial strategy development and both Pharmacyclics and Janssen will share in commercialization activities.    Outside the United States, Janssen will book sales a
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  Inari Medical, Inc. announced ... B venture capital financing. The financing was led by ... Versant Ventures and US Venture Partners.  The round also ... "We are very pleased to complete this financing ... Bill Hoffman , who joined in February 2015 ...
(Date:6/30/2015)... , June 30, 2015  Avanir Pharmaceuticals, Inc. ... study showing that treatment with NUEDEXTA ® ... symptoms of pseudobulbar affect (PBA) in patients with ... a distressing condition characterized by sudden and uncontrollable ... neurologic diseases or brain injury. PRISM II is ...
(Date:6/30/2015)... NEW YORK , June 30, 2015 /PRNewswire/ – ... ARYC) had an agreement to supply custom Arrayit blood ... private human DNA vault on earth. Vivos offers an ... provide virtually every man, woman and child on Earth, ... store their DNA. Arrayit blood cards allow the rapid ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7Small Cap IR - Empowering the Age of Genetic Enlightenment 2
... Sigma-Aldrich Corporation (NASDAQ: SIAL ) today announced ... ( www.safcglobal.com ), is introducing a novel CHOZN® GS-/- ... line. Designed for use in the production of biopharmaceuticals, ... commercially available glutamine synthetase (GS) knockout CHO cell line ...
...  The Eli Lilly and Company Foundation has committed US $30 ... in its fight against multidrug-resistant tuberculosis – a disease that ... each year. The announcement was made ahead of the opening ... Lille, France, later this week. Eli Lilly ...
Cached Medicine Technology:SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 2SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 3SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 4Lilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership 2Lilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership 3Lilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership 4Lilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership 5
(Date:6/30/2015)... ... 2015 , ... Tulika Ranjan, MD, a prominent neuro-oncologist from ... as Director of its Adult Neuro-Oncology program. , Dr. Ranjan’s clinical ... disease and the neurological complications of cancer. She has special expertise in ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... Joe Kennedy III (D-MA) and Danny Davis (D-IL) for writing to the Department ... investigation into the nation’s largest behavioral healthcare system, Universal Health Services (UHS).[1] CCHR ...
(Date:6/30/2015)... ... 2015 , ... The League for Innovation in the Community ... Predictive Analytics Reporting (PAR) Framework, and Susan Rundell Singer, Director of the Division ... at the 2015 STEMtech conference in Phoenix, Arizona, November 1-4. , Opening ...
(Date:6/30/2015)... ... June 30, 2015 , ... Amerec, a division of TyloHelo Inc, is pleased ... Daily is now approved by the Interior Design Continuing Education Council for 1 credit ... overview and explanation of what sauna, steam, and far-infrared saunas are, where they are ...
(Date:6/30/2015)... ... June 30, 2015 , ... People ... face in the aftermath of a near-death experience (NDE) – and also want ... providing adequate treatment options – are invited to visit https://zoom.us/webinar/register/f4a12556fe7c03f5dc2040ba88984b7b ...
Breaking Medicine News(10 mins):Health News:Noted Duke Brain Cancer Specialist to Direct Allegheny Health Network Neuro-Oncology Program 2Health News:Noted Duke Brain Cancer Specialist to Direct Allegheny Health Network Neuro-Oncology Program 3Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 2Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 3Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 4Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 5Health News:League for Innovation Announces Distinguished Keynote Presenters for STEMtech Conference 2Health News:League for Innovation Announces Distinguished Keynote Presenters for STEMtech Conference 3Health News:Amerec’s Steam and Sauna Continuing Education Course Now Approved for Interior Design Credit 2Health News:IANDS Sponsors No-Cost Webinar on July 1/15 at 11CST Featuring Combat Soldier Who Survived Near-Death Experience 2Health News:IANDS Sponsors No-Cost Webinar on July 1/15 at 11CST Featuring Combat Soldier Who Survived Near-Death Experience 3
... NEW YORK, N.Y. (September 13, 2011) For children ... as having their blood drawn can be very difficult. ... routines experienced by many children with ASD are the ... with ASD for a blood draw. In an effort ...
... News) -- Researchers have found dozens of new genetic variants ... Although more than 300 genes for cardiovascular diseases have ... Hopkins have recently identified 29 more DNA sequence variations. The ... disease and stroke, they reported. "A genetic risk score ...
... WASHINGTON, Sept. 13By combining three previously unrelated imaging tools ... the University of Connecticut and the University of Southern ... ovarian cancer in high-risk women through minimally invasive surgery. ... standard procedure of preemptively removing the ovaries. ...
... leadership, communication and teamwork are essential to successful ... organizations achieve improvement is not clearly understood, says ... professor in the Sinclair School of Nursing, found ... and relationship building to generate improvement, such as ...
... Intrauterine devices (IUDs) may protect against cervical cancer. This is ... which has participated the research group in Viruses and Cancer ... The results show that women who uses IUD halved the ... not ever used. These results are contrary to popular belief ...
... , TUESDAY, Sept. 13 (HealthDay News) -- ... atherosclerosis, a condition caused by the build-up of plaque ... according to new research. In conducting the study, ... Lancet , researchers followed 130 patients with atherosclerosis who ...
Cached Medicine News:Health News:Autism Speaks launches 'blood draw' tool kit -- practical guidance for parents and providers 2Health News:Autism Speaks launches 'blood draw' tool kit -- practical guidance for parents and providers 3Health News:Newly Found Gene Mutations May Aid Heart Treatments 2Health News:Strong leadership necessary to provide more sophisticated care for aging population, study finds 2Health News:IUD reduces the risk of cervical cancer 2Health News:New Drug Boosts 'Good' Cholesterol in Study Patients 2
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Medium 23 mm. Overall length: 3.9 inches....
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Short 19 mm. Overall length: 3.9 inches....
Size 2 dilator. Stainless steel. Round knurled handle with polished finish. Overall length: 4 inches....
Double ended dilator probes with gentle curve. Stainless steel. Round knurled handle with polished finish. Overall length: 5.3 inches....
Medicine Products: